
PRESS RELEASE

FOR IMMEDIATE RELEASE

November 18, 2024

Well Cell Global LLC and Insulinic LLC Forge Strategic Alliance to Advance Metabolic Disorder Programs

HOUSTON, TEXAS – Well Cell Global LLC (“Well Cell Global”) and Insulinic LLC (“Insulinic”) are pleased to announce the resolution of prior disputes and the establishment of a new strategic partnership. This collaboration aims to revolutionize the support provided to physicians treating patients with metabolic disorders.

The International Diabetes Federation estimates that 540 million people worldwide live with diabetes. According to the American Diabetes Association, 84 million Americans are at risk of developing Type 2 diabetes. Over the years, Well Cell Global has dedicated its efforts to assisting physicians in managing chronic conditions associated with diabetes, such as chronic kidney disease, diabetic retinopathy, neuropathy, obesity, and other severe complications, including the prevention of amputations and dialysis.

By merging Well Cell’s cutting-edge biotech and intellectual property advancements with Insulinic’s robust business model, the alliance aims to expand its reach significantly, not only across the United States but globally. The focus is on developing innovative programs to assist patients with diabetes and other metabolic disorders more effectively.

Both companies have extensive operations across the United States and have broadened their international footprint. This collaboration enables them to swiftly translate their plans into actionable solutions, benefiting millions of diabetes patients and those at risk, along with their families and caregivers.

“With our shared commitment to the future, we foresee unlimited advancements and improvements for diabetic patients worldwide,” said Scott Hepford, CEO of Well Cell Global. Shawn Calvit, CEO of Insulinic, added, “This strategic alliance will allow both of our companies to focus our talents, energies, and financial resources on achieving our common goals of improving the lives of all diabetes patients.”

For further information, please visit www.wellcellglobal.com and www.insulinic.com.

Contact: Carol Wilson, carol@wellcellsupport.com, 281-713-5999 x112